Introduction of these variants, found in individuals with bipolar disorder, schizophrenia, and epilepsy, into GEF2 altered nucleotide exchange rates on RhoA, with some mutations significantly increasing the catalytic activity of GEF2. The gene discussed is GABARAPL2; the disease is schizophrenia.